[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346031-105":59,"doc-detail-346031-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-local-effects-of-systemic-therapies-in-urological-oncology-a-systematic-review","The Local Effects of Systemic Therapies in Urological Oncology - A Systematic Review","","Systemic therapies may influence local disease progression in genitourinary malignancies, with the goal of reducing or eliminating extensive surgery. A systematic review searched PubMed and Scopus through May 2026 for studies linking preoperative systemic treatment to surgical outcomes across prostate, kidney, testicular, and bladder cancers. Results address margins, organ confinement, tumor response, recurrence endpoints, and evidence from key drug classes and biomarkers, culminating in guidance toward clinical-trial strategies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-local-effects-of-systemic-therapies-in-urological-oncology-a-systematic-review/346031/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-local-effects-of-systemic-therapies-in-urological-oncology-a-systematic-review/346031.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of this systematic review?","Question",{"text":112,"@type":113},"To determine how systemic therapies affect local disease progression and surgical outcomes in genitourinary cancers, and whether they can reduce the need for extensive local surgery.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did neoadjuvant hormonal therapy show in prostate cancer?",{"text":117,"@type":113},"It improved margin status and organ confinement, but did not improve biochemical-free survival, and chemotherapy or immunotherapy showed no clinical benefit in the reviewed evidence.",{"name":119,"@type":110,"acceptedAnswer":120},"How do systemic therapies affect bladder cancer surgical outcomes?",{"text":121,"@type":113},"In muscle-invasive bladder cancer, cisplatin-based chemotherapy produced pathological complete response in about one-third of patients, and adding immunotherapy or antibody-drug conjugates further improved pCR rates.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346031,1790875010,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Cancer Medicine  \nREVIEW  OPEN ACCESS   \nThe Local Effects of Systemic Therapies in Urological Oncology: A Systematic Review  \nSharon Nordheimer1 | Ofer N. Gofrit2   \n1Department of Oncology, Hadassah University Hospital, Jerusalem, Israel | 2Department of Urology, Hadassah University Hospital, Jerusalem, Israel Correspondence: Ofer N. Gofrit ([ogofrit@gmail.com](ogofrit@gmail.com))  \nReceived: 17 June 2025 | Revised: 15 August 2026 | Accepted: 18 August 2026  \nKeywords: biomarkers | chemotherapy | immunotherapy | neoadjuvant | response | surgery | uro-oncology  \nABSTRACT  \nBackground: Systemic therapies can impact local disease progression in genitourinary malignancies, potentially reducing the necessity for extensive surgery. Understanding these effects is crucial for optimizing treatment approaches in urologic oncology. Methods: Through PubMed and Scopus databases search up to May 2026, we identified studies focusing on surgical outcomes after systemic therapy in prostate, kidney, testicular, and bladder cancers.  \nResults: In prostate cancer (PC), neoadjuvant hormonal therapy improved margin status and organ confinement but did not enhance biochemical-free survival rates. Chemotherapy or immunotherapy provided no clinical benefit. In kidney cancer, tyrosine kinase inhibitors and immune checkpoint inhibitors reduced tumor diameter by 13.5%–35% but did not improve recurrence-free survival. Certain therapeutic combinations decreased vena cava thrombus length, lessening surgical complexity. Post-chemotherapy, testicular cancer specimens revealed viable tumors in 8.3%–25% of cases, teratomas in 18.2%–50.0%, and scar or in situ neoplasms in 31.1%–60.0% of specimens. In muscle-invasive bladder cancer, cisplatin-based chemotherapy resulted in a pathological complete response (pCR) in approximately one-third of patients, and the addition of immunotherapy or antibody-drug conjugates further improved pCR rates. Molecular markers such as circulating tumor DNA and urine tumor DNA are being investigated as potential markers for predicting pCRs.  \nConclusions: Current systemic therapies do not eliminate the need for radical orchiectomy, nephrectomy, or local treatment in PC. The ability to avoid radical surgery in bladder cancer is still investigational. Therefore, attempts to avoid local treatment inpatients with genitourinary malignancies should be pursued within the framework of a clinical trial.  \n1 | Introduction  \nLocal treatments in genitourinary malignancies often include complex and mutilative surgeries in patients with multiple comorbidities, and are associated with a decrease in quality of life and often with post-treatment complications. If systemic treatment could decrease the extent of local treatment or even totally eliminate it, this would be highly beneficial. This concept justifies review of the local effects of systemic therapies. Most information comes from studies on neoadjuvant treatments administered prior to extirpative surgery in patients with muscleinvasive bladder cancer (MIBC) and high-burden testicular  \ncancer. Efforts have also been made to improve the prognosis of patients with localized kidney and prostate malignancies. The primary goal of these treatments is the elimination of micrometastatic disease, but a local effect is also expected. This review addresses the following questions:  \n1. Can systemic treatment sterilize the primary disease?  \n2. Can systemic treatment improve prognosis in patients with localized disease?  \n3. Can systemic treatment modify surgical strategy, making it less mutilative, complex, and prone to complications?  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine, 2026; 15:e72211 1 of","cbCailKnXdgz9098","https://ap.wps.com/l/cbCailKnXdgz9098","pdf",655608,12,"English","# Abstract\n# Introduction\n# Materials and Methods\n# Prostate Cancer (Table 1)\n## Studies With Antiandrogens","[{\"question\":\"What is the main purpose of this systematic review?\",\"answer\":\"To determine how systemic therapies affect local disease progression and surgical outcomes in genitourinary cancers, and whether they can reduce the need for extensive local surgery.\"},{\"question\":\"What did neoadjuvant hormonal therapy show in prostate cancer?\",\"answer\":\"It improved margin status and organ confinement, but did not improve biochemical-free survival, and chemotherapy or immunotherapy showed no clinical benefit in the reviewed evidence.\"},{\"question\":\"How do systemic therapies affect bladder cancer surgical outcomes?\",\"answer\":\"In muscle-invasive bladder cancer, cisplatin-based chemotherapy produced pathological complete response in about one-third of patients, and adding immunotherapy or antibody-drug conjugates further improved pCR rates.\"}]","The Local Effects of Systemic Therapies in Urological Oncology - A Systematic Review | PDF",1790059764,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26c18417f7a4f6c1cce0b2ec2eb417c9.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa657869fca3e4221dc9a094e3fb6bba.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9acbf5cba4493c7e8e128c76b02b9dec.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b592f021c47af0429a41d070b5cbc4c2.webp",980,1287]